Fierce Biotech1 min read
saveJ&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.
comments(0)
5-min edit window · permanent after that